Cathie Wood, a prominent advocate for innovative technologies, is making a bold bet on artificial intelligence with her latest investment in Tempus AI Inc. (NASDAQ: TEM).
Known for her strategic focus on transformative technologies, Wood’s decision to heavily invest in Tempus reflects her confidence in the company’s potential within the burgeoning AI health-tech sector.
Tempus stock, which debuted on the Nasdaq Stock Exchange in June at around $40, has surged over 50% since its initial offering, underscoring growing investor enthusiasm.
Wood allocates $1.5 million to Tempus AI
Wood has recently allocated over $1.5 million to Tempus AI through two of her flagship funds.
This investment comes at a time when Tempus shares were trading at a 15% discount compared to their peak in July, suggesting that Wood’s investments are already yielding significant returns.
The AI-driven health-tech company specializes in creating precision medicines tailored to individual patients, addressing conditions such as depression, cardiac issues, and oncological complications.
This innovative approach has garnered a consensus “buy” rating from Wall Street analysts, reflecting strong confidence in Tempus’s future growth.
Despite its promising technology and substantial revenue of over $530 million last year, Tempus is not yet profitable.
Wood’s investment strategy also involved replacing Teladoc Health in her portfolio with Tempus due to Teladoc’s recent financial underperformance and withdrawal of its full-year guidance.
Should you invest in Natera?
In addition to Tempus, Wood has also shown interest in Natera Inc. (NASDAQ: NTRA), another health-tech company.
While Natera’s stock has nearly doubled this year and its recent earnings exceeded expectations by 50%, it comes with its own set of risks.
The clinical genetic testing firm is currently embroiled in a lawsuit alleging unfair billing practices.
This legal challenge follows a previous settlement with the Department of Justice for $11 million in 2018 over similar issues.
The ongoing legal troubles add a layer of uncertainty to Natera’s investment appeal.
Although not all lawsuits result in negative outcomes for companies, they can impact investor confidence and stock performance.
Potential investors are advised to exercise caution when considering investments in companies facing significant legal challenges.
Will Tempus AI be a good bet?
Cathie Wood’s substantial investment in Tempus AI highlights her belief in the company’s ability to capitalize on the growing demand for AI-driven health solutions.
With its innovative approach to precision medicine and a strong revenue track record, Tempus represents a potentially lucrative opportunity in the health-tech sector.
However, investors should remain vigilant about the risks associated with other investments, such as Natera, which, despite strong financials, faces legal hurdles that could influence its future performance.
As Wood continues to navigate the rapidly evolving technology landscape, Tempus AI stands out as a key player in the AI health-tech field.
Whether it will maintain its upward trajectory and deliver on its promise remains to be seen, but Wood’s investment underscores a significant vote of confidence in the company’s potential.
The post Cathie Wood bets big on Tempus AI: Is it the next big thing in health-tech? appeared first on Invezz
